I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021 The current U.S. NHL clinical trial has now expanded to include clinical sites in China as an international multi-center clinical trial, which will potentially lead to a registrational trial...
Broncus Completed the First-in-man Clinical Trial of Its Targeted Lung Denervation Radiofrequency Ablation System
HONG KONG, Sept. 30, 2021 /PRNewswire/ -- Broncus Holding Corporation ("Broncus" or the "Company") is pleased to announce that it has completed the first-in-man clinical trial of its Targeted Lung Denervation (TLD) radiofrequency ablation system, which is expected to benefit patients with chronic obstructive pulmonary disease ("COPD") worldwide. The clinical operation was completed by a team consisting of Professor...
Zantrene® kills melanoma cancer cells that overproduce FTO
Zantrene® at low concentrations kills high FTO producing melanoma cancer cells Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells Results are highly supportive of future clinical trials in melanoma using Zantrene® in combination with standard of care treatments. SYDNEY, Sept....
EZZ Delivers Strong FY21 Operational Performance, Declares Dividend
SYDNEY, Sept. 30, 2021 /PRNewswire/ -- EZZ Life Science Holdings Limited (ASX: EZZ), a producer of consumer health products and the exclusive wholesale distributor of the EAORON skin care products for pharmacies, supermarkets and retailers in Australia and New Zealand, presents its full year statutory accounts for the period ended June 30, 2021 (FY21) and announces its maiden full...
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor
GUANGZHOU, China, Sept. 30, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, and Innovent Biologics (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient with KRAS G12C mutation has been dosed...
Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, Sept. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351 in Chinese patients with solid tumors (ClinicalTrials.gov, NCT05005234) completed...
How we can all help improve standards of care for children with clefts to optimize their oral health
FDI World Dental Federation (FDI) releases new educational resources to mark World Smile Day® GENEVA, Sept. 30, 2021 /PRNewswire/ -- Globally, every three minutes a baby is born with a cleft, that's 540 babies every day. Babies born with a cleft often struggle to eat, breathe, hear, speak, and thrive. Every child has the right to good oral health, which...
ObvioHealth Partners with Anatara Lifesciences to Launch First-of-its-kind Decentralized Clinical Trial in Australia
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia, using a combination of in-home data collection methods that will reduce, and in some cases, eliminate the need for follow-up visits to clinics. The randomized, double-blind, placebo-controlled trial with Anatara Lifesciences (ASX:ANR)...
SHOW JIANGSU Media Tour visit Jiangsu Suyun Medical Materials in Lianyungang
LIANYUNGANG, China, Sept. 29, 2021 /PRNewswire/ -- On 18 September 2021, SHOW JIANGSU Media Tour was held in Lianyungang, Jiangsu province. Jiangsu Suyun Medical Materials Co.,Ltd is a medical material supplier that produces blood-infusion sets, tubes, catheter and other medical equipment, according to the Information Office of Lianyungang Municipal People's Government. A woman works in a Suyun...
Nanoform receives funding to solve challenges for global health
HELSINKI, Sept. 29, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation to assess the added value Nanoform's award-winning CESS® nanoparticle engineering technology can deliver to several of its drug development projects. Nanoform is working to develop nanomedicines with the ultimate aim...
